UNITED STATES OF AMERICA

DEPARTMENT OF TRANSPORTATION

OFFICE OF THE SECRETARY

WASHINGTON, DC

                         Issued by the Department of Transportation on
September 2, 2005

           NOTICE OF ACTION TAKEN

        DOCKET OST-2005-21816

________________________________________________________________________
______________________________________________________________

This serves as notice to the public of the action described below, taken
by the Department official indicated (no additional confirming order
will be issued in this matter).

Application of  Brendan Airways, LLC, d/b/a USA 3000 (USA 3000)  filed
7/7/05 for:

XX  Exemption for two years under 49 U.S.C. 40109 to provide the
following service:

Scheduled foreign air transportation of persons, property, and mail
between Detroit, Michigan, and Zihuatanejo/Ixtapa, Mexico.  USA 3000
proposes seasonal service in the market, beginning December 24, 2005.

Applicant rep:  Pierre Murphy<PHONE_NUMBER>   DOT Analyst:  Linda
Lundell<PHONE_NUMBER>

D I S P O S I T I O N

XX  Granted (subject to conditions, see below)

The above action was effective when taken:  September 2, 2005, through
September 2, 2007.

Action taken by:   Paul L. Gretch, Director

		    Office of International Aviation

XX  The authority granted is consistent with the aviation agreement
between the United States and Mexico.

Except to the extent exempted or waived, this authority is subject to
the terms, conditions, and limitations indicated:

XX Holder’s certificates of public convenience and necessity

XX  Standard exemption conditions (attached)

Conditions:  The U.S.-Mexico exemption authority granted is subject to
the dormancy notice requirements set forth in condition 7 of Appendix A
of Order 88-10-2, and the notice requirements for seasonal/intermittent
services as set forth in Order 96-11-24, at 5.  Consistent with our
standard policy, the dormancy notice period for the exemption authority
granted will begin on December 24, 2005, USA 3000’s proposed start-up
date for the subject services.

________________________________________________________________________
____________________________________

On the basis of data officially noticeable under Rule 24(g) of the
Department's regulations, we found the applicant qualified to provide
the exemption services authorized.

Under authority assigned by the Department in its regulations, 14 CFR
Part 385, we found that (1) our action was consistent with Department
policy; (2) grant of the authority was consistent with the public
interest; and (3) grant of the authority would not constitute a major
regulatory action under the Energy Policy and Conservation Act of 1975.
To the extent not granted, we denied all requests in the referenced
Dockets.  We may amend, modify, or revoke the authority granted in this
Notice at any time without hearing at our discretion.

Persons entitled to petition the Department for review of the action set
forth in this Notice under the Department’s regulations, 14 CFR
§385.30, may file their petitions within seven (7) days after the date
of issuance of this Notice.  This action was effective when taken, and
the filing of a petition for review will not alter such effectiveness.

An electronic version of this document is available on the World Wide
Web at:

  HYPERLINK "http://dms.dot.gov//reports/reports_aviation.asp"
http://dms.dot.gov//reports/reports_aviation.asp

			APPENDIX

U.S. Carrier Exemption Conditions

In the conduct of the operations authorized, the U.S. carrier
applicant(s) shall:

(1)  Hold at all times effective operating authority from the government
of each country served;

(2)  Comply with applicable requirements concerning oversales contained
in 14 CFR 250 (for scheduled operations, if authorized);

(3)  Comply with the requirements for reporting data contained in 14 CFR
241;

(4)  Comply with requirements for minimum insurance coverage, and for
certifying that coverage to the Department, contained in 14 CFR 205;

(5)  Except as specifically exempted or otherwise provided for in a
Department Order, comply with the requirements of 14 CFR 203, concerning
waiver of Warsaw Convention liability limits and defenses;

(6)  Comply with all applicable requirements of the Federal Aviation
Administration and with all applicable U.S. Government requirements
concerning security, including, but not limited to, 49 CFR Part 1544.
To assure compliance with all applicable U.S. Government requirements
concerning security, the holder shall, before commencing any new service
(including charter flights) to or from a foreign airport, contact its
International Principal Security Inspector (IPSI) to advise the IPSI of
its plans and to find out whether the Transportation Security
Administration has determined that security is adequate to allow such
airport(s) to be served; and

(7)  Comply with such other reasonable terms, conditions, and
limitations required by the public interest as may be prescribed by the
Department of Transportation, with all applicable orders and regulations
of other U.S. agencies and courts, and with all applicable laws of the
United States.

The authority granted shall be effective only during the period when the
holder is in compliance with the conditions imposed above.

05/2004

 PAGE

 PAGE   3


[Federal Register Volume 76, Number 105 (Wednesday, June 1, 2011)]
[Notices]
[Page 31606]
[FR Doc No: 2011-13584]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2011-0173; FRL-8875-8]

Cryolite Registration Review Docket; Extension of Comment Period

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice; extension of comment period.

-----------------------------------------------------------------------

SUMMARY: EPA issued a notice in the Federal Register of March 30, 2011
concerning the availability of multiple registration review dockets for
public comment, including cryolite. This document extends the comment
period for the cryolite registration review docket only, which was due
to expire on May 31, 2011, until July 5, 2011.

DATES: Comments, identified by docket identification (ID) number EPA-
HQ-OPP-2011-0173, must be received on or before July 5, 2011.

ADDRESSES: Follow the detailed instructions as provided under ADDRESSES
in the Federal Register document of March 30, 2011.

FOR FURTHER INFORMATION CONTACT: Eric Miederhoff, Pesticide Re-
evaluation Division (7508P), Office of Pesticide Programs,
Environmental Protection Agency, 1200 Pennsylvania Ave., NW.,
Washington, DC 20460-0001; telephone number:<PHONE_NUMBER>; e-mail
address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: This document extends the public comment
period established in the Federal Register of March 30, 2011 (76 FR
17646) (FRL-8868-9). In that document, the Agency announced the
availability of multiple registration review dockets for public
comment, including cryolite. EPA is hereby extending the comment period
for the cryolite registration review docket only until July 5, 2011.
    To submit comments, or access the docket, please follow the
detailed instructions as provided under ADDRESSES in the March 30, 2011
Federal Register document. If you have questions, consult the person
listed under FOR FURTHER INFORMATION CONTACT.

List of Subjects

    Environmental protection, Cryolite, Pesticides and pests.

    Dated: May 25, 2011.
Peter Caulkins,
Acting Director, Pesticide Re-evaluation Division, Office of Pesticide
Programs.
[FR Doc. 2011-13584 Filed 5-26-11; 4:15 pm]
BILLING CODE 6560-50-P


[Federal Register Volume 88, Number 234 (Thursday, December 7, 2023)]
[Notices]
[Pages 85296-85298]
[FR Doc No: 2023-26886]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2015-D-3517]

Interim Policy on Compounding Using Bulk Drug Substances Under
Section 503A of the Federal Food, Drug, and Cosmetic Act; Draft
Guidance for Industry; Availability.

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a draft guidance for industry entitled ``Interim
Policy on Compounding Using Bulk Drug Substances Under section 503A of
the Federal Food, Drug, and Cosmetic Act'' (draft guidance or 2023 503A
Interim Policy Draft Guidance) to describe FDA's interim policy
regarding the use of bulk drug substances by human drug compounders
that are not registered with FDA as outsourcing facilities while FDA
develops the list of bulk drug substances that can be used in
compounding under the applicable section of the Federal Food, Drug, and
Cosmetic Act (FD&C Act). This draft guidance, when finalized, will
replace the guidance for industry entitled, ``Interim Policy on
Compounding Using Bulk Drug Substances under section 503A of the
Federal Food, Drug, and Cosmetic Act'' issued in January 2017 (2017
503A Interim Policy Guidance).

DATES: Submit either electronic or written comments on the draft
guidance by January 8, 2024 to ensure that the Agency considers your
comment on this draft guidance before it begins work on the final
version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as
follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2015-D-3517 for ``Interim Policy on Compounding Using Bulk Drug
Substances Under Section 503A of the Federal Food, Drug, and Cosmetic
Act.'' Received comments will be placed in the docket and, except for
those submitted as ``Confidential Submissions,'' publicly viewable at
https://www.regulations.gov or at the Dockets Management Staff between
9 a.m. and 4 p.m., Monday through Friday,<PHONE_NUMBER>.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.
    You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
    Submit written requests for single copies of the draft guidance to
the Division of Drug Information, Center for Drug Evaluation and
Research, Food and Drug Administration, 10001 New Hampshire Ave.,
Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one
self-addressed adhesive label to assist that office in processing your
requests. See the SUPPLEMENTARY INFORMATION section for electronic
access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Mariestela Buhay, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 5199, Silver Spring, MD 20993-0002,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of a draft guidance for industry
entitled ``Interim Policy on Compounding Using Bulk Drug Substances
Under section 503A of the Federal Food, Drug, and Cosmetic Act.'' This
draft guidance, when finalized, will replace the 2017 503A Interim
Policy Guidance, available at https://www.fda.gov/media/94398/download.
Section 503A of the FD&C Act (21 U.S.C. 353a) describes the conditions
that must be satisfied for human drug products compounded by a licensed
pharmacist in a State-licensed pharmacy or Federal facility, or by a
licensed physician, to be exempt from the following three sections of
the FD&C Act: (1) section 505 (21 U.S.C. 355) (concerning the approval
of drugs under new drug applications or abbreviated new drug
applications); (2) section 502(f)(1) (21 U.S.C. 352(f)(1)) (concerning
the labeling of drugs with adequate directions for use); and (3)
section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)) (concerning current good
manufacturing practice requirements). One of the conditions that must
be met for a compounded drug product to qualify for these exemptions is
that a licensed pharmacist or licensed physician compounds the drug
product using bulk drug substances that (1) comply with the standards
of an applicable United States Pharmacopeia (USP) or National Formulary
(NF) monograph, if a monograph exists, and the USP chapters on pharmacy
compounding; (2) if such a monograph does not exist, are drug
substances that are components of drugs approved by the Secretary of
the Department of Health and Human Services (Secretary); or (3) if such
a monograph does not exist and the drug substance is not a component of
a drug approved by the Secretary, appears on a list developed by the
Secretary through regulations issued by the Secretary under subsection
(c) of section 503A of the FD&C Act (the 503A bulks list). (See section
503A(b)(1)(A)(i) of the FD&C Act.)
    This draft guidance, when finalized, will revise FDA's current
interim policy with respect to categorization of certain substances
nominated for inclusion on the 503A bulks list. The guidance, when
finalized, will end the categorization of bulk drug substances into
Categories 1, 2, or 3 for those bulk drug substances nominated on or
after the date of publication of the final guidance.
    The 2017 503A Interim Policy Guidance describes the conditions
under which FDA does not intend to take action against a State-licensed
pharmacy, Federal facility, or physician for compounding drug products
using certain bulk drug substances that are not eligible for use in
compounding under

section 503A because they are not the subject of an applicable USP or
NF monograph, components of FDA-approved drug products, or on the 503A
bulks list. One of those conditions is that the bulk drug substance
appears in Category 1. If the 2023 503A Interim Policy Draft Guidance
is finalized in its current form, a substance nominated on or after the
date of publication of that final guidance would not be categorized and
would not be within the scope of the policy for substances that appear
in Category 1.\1\ However, FDA would consider the substance for
inclusion on the 503A bulks list in accordance with the process and
criteria established in the FD&C Act and FDA regulations (see section
503A(b)(1)(A) of the FD&C Act and 21 CFR 216.23(c)). Substances that
already appear in Category 1 (including substances nominated with
adequate supporting information prior to the date of publication of the
final guidance) may continue to be eligible for the policy that applies
to Category 1 substances, as described in the final guidance, until FDA
promulgates a final rule determining whether they will be placed on the
503A bulks list in accordance with section 503A(b)(1)(A)(i)(III) of the
FD&C Act or unless the Agency removes the substances from Category 1
based on, for example, information about safety risks.
---------------------------------------------------------------------------

    \1\ FDA recognizes that some compounders and other stakeholders
may currently be in the process of compiling a nomination for the
503A bulks list for submission to the Agency. FDA intends to
categorize nominations of bulk drug substances received prior to the
date in which FDA announces the availability of the final guidance.
FDA believes that this will provide a sufficient amount of time in
which to submit nominations that are currently in progress.
---------------------------------------------------------------------------

    FDA encourages interested parties to focus their comments on the
limited revisions to the interim policy included, for public comment,
in the 2023 503A Interim Policy Draft Guidance.
    This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the current thinking of FDA on ``Interim
Policy on Compounding Using Bulk Drug Substances Under Section 503A of
the Federal Food, Drug, and Cosmetic Act.'' It does not establish any
rights for any person and is not binding on FDA or the public. You can
use an alternative approach if it satisfies the requirements of the
applicable statutes and regulations.

II. Paperwork Reduction Act of 1995

    FDA tentatively concludes that this draft guidance contains no
collection of information. Therefore, clearance by the Office of
Management and Budget under the Paperwork Reduction Act of 1995 is not
required.

III. Electronic Access

    Persons with access to the internet may obtain the draft guidance
at https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.regulations.gov.

    Dated: December 1, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-26886 Filed 12-6-23; 8:45 am]
BILLING CODE 4164-01-P


Walt Stevenson/ RTP/ USEPA/ US 04/ 14/ 2006 10: 40 AM To edmond_ toy@ omb. eop. gov cc RobertJ Wayland/ RTP/ USEPA/ US@ EPA, Brian Shrager/ RTP/ USEPA/ US@ EPA Subject UCL 99.7 and 99 / LMWC 5 ye review Edmond Attached below is the revised text we have used to hopefully better explain the UCL issue.

take care Walt H. What emission variability factor is appropriate?

Although most commenters and EPA used similar statistical methodology, differences were identified in assumptions used to develop emission variability factors ( in particular, the upper confidence limit ( UCL)). The UCL addresses how often, on average, one would estimate that an emissions level may exceed a certain value ( the standard).

For analysis of CEMS data, such as sulfur dioxide or nitrogen oxides, where 365 tests ( 24 hr CEMS average) are conducted per year, EPA and commenters agreed the emission limit should be set at a level that would be expected to be exceeded only once per year at a well operated MWC plant.

Once per year translates into a 99.7 percent UCL ( 364/ 365 = 0.997 or 99.7 percent). A number of commenters suggested the use of a 99.7 percent UCL for development of limits using both CEMS data ( sulfur dioxide and nitrogen oxide)

and stack test data ( cadmium, lead, mercury, particulate matter, dioxin, and hydrogen chloride). This is one area where EPA disagrees with these commenters. EPA concludes a different assumption is appropriate for stack test compliance procedures. For compliance determination by stack test, EPA used a different and lower UCL. One must remember when using a stack test for determining compliance ( cadmium, lead, mercury, particulate matter, dioxin, and hydrogen chloride), only one stack test is conducted per year, in contrast to the continuous measurements provided by CEMS. Over the 30 year life of a facility, only 30 stack tests would have occurred. This needs to be reflected in the emission limits. The actual stringency of an emissions limit is affected by how often one tests. In fact, using the same data distribution, same emission limit, and same UCL, the stringency of standard is affected by adjusting just the testing schedule. For example, assuming a 99.7 UCL , if one tests every day using a CEMS over the 30 year life of an MWC as compared to testing only once per year over the same 30 year life of the MWC, one will find the probability of exceeding the standard noticably higher with the CEMS. In this example, one would in fact find the probability of exceeding the standard about ten times as high if CEMS are used. (( 1(. 997^ 30x365))/( 1 (. 997^ 30))= 11.6 ) In consideration of this, EPA reduced the UCL for stack test analysis to 99 percent. Even lower UCL could be considered, however, EPA reviewed actual year 2000 to 2005 data to judge the reasonableness of the estimates and conclude 99 percent UCL presented reasonable estimates for stack test pollutants.


[Federal Register Volume 75, Number 242 (Friday, December 17, 2010)]
[Rules and Regulations]
[Pages 78928-78929]
[FR Doc No: 2010-31699]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

46 CFR Part 45

[Docket No. USCG-1998-4623]
RIN 1625-AA17

Limited Service Domestic Voyage Load Lines for River Barges on
Lake Michigan, Delay of Effective Date

AGENCY: Coast Guard, DHS.

ACTION: Notice of delay of effective date and reopening of the comment
period.

-----------------------------------------------------------------------

SUMMARY: The Coast Guard announces that it is delaying the effective
date of certain revisions in 46 CFR part 45 as amended by the final
rule published in the November 18, 2010, Federal Register (75 FR
70595), and soliciting comments on those amendments.

DATES: Effective Date. This action is effective December 20, 2010. The
effective date of revisions to 46 CFR Table 45.171, Sec.  45.187, and
Sec.  45.191(a), as revised in the final rule published in the November
18, 2010, Federal Register (75 FR 70595) is delayed until June 15,
2011. All other provisions of the final rule are effective on December
20, 2010.
    Comment Period. Comments must be received at the address provided
below no later than January 18, 2011. Comments are limited to the
subject matter described below.

ADDRESSES: You may submit comments identified by docket number USCG-
1998-4623 using any one of the following methods:
    (1) Federal eRulemaking Portal: http://www.regulations.gov.
    (2) Fax:<PHONE_NUMBER>.
    (3) Mail: Docket Management Facility (M-30), U.S. Department of
Transportation, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue, SE., Washington, DC 20590-0001.
    (4) Hand delivery: Same as mail address above, between 9 a.m. and 5
p.m., Monday through Friday, except Federal holidays. The telephone
number is<PHONE_NUMBER>.
    To avoid duplication, please use only one of these four methods.
See the ``Public Participation and Request for Comments'' portion of
the SUPPLEMENTARY INFORMATION section below for instructions on
submitting comments.
    Comments and material received from the public, as well as
documents mentioned in this preamble as being available in the docket,
are part of docket USCG-1998-4623 and are available for inspection or
copying at the Docket Management Facility (M-30), U.S. Department of
Transportation, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue, SE., Washington, DC 20590, between 9 a.m. and 5 p.m.,
Monday through Friday, except Federal holidays. You may also find this
docket on the Internet by going to http://www.regulations.gov,
inserting USCG-1998-4623 in the ``Keyword'' box, and then clicking
``Search.''

FOR FURTHER INFORMATION CONTACT: If you have questions on this rule,
call or e-mail Mr. Thomas Jordan, Office of Design and Engineering
Standards, Naval Architecture Division (CG-5212), Coast Guard;
telephone<PHONE_NUMBER>, e-mail<EMAIL_ADDRESS>If you have
questions on viewing or submitting material to the docket, call Ms.
Renee V. Wright, Program Manager, Docket Operations, telephone 202-366-
9826.

SUPPLEMENTARY INFORMATION:

Background and Purpose

    On November 18, 2010, the Coast Guard published a final rule (75 FR
70595) regarding special load line regimes for certain river barges
operating on Lake Michigan. This rule finalized interim regulations
that have been in effect since 2002, with some changes. The final
regulations are scheduled to go into effect on December 20, 2010. For
reasons explained herein, we are extending the effective date of the
revised weather restrictions (found in 46 CFR Table 45.171, Sec.
45.187, and Sec.  45.191(a) of the final rule) for 6 months and
requesting public comment on that provision.
    United States vessels operating on Lake Michigan are normally
required to have a load line assignment. River barges do not typically
qualify for load line assignment because their hull construction is not
robust enough for unrestricted operations on the Great

Lakes. However, we have established special load line regimes whereby
certain river barges may operate on select Great Lakes routes under
limited conditions. These are conditional exemptions: The barges are
exempted from the normal Great Lakes load line requirement only if they
comply with the specified provisions for the route. On all routes, the
tows are restricted to not more than 5 nautical miles from shore. And
because river barges are not as robustly constructed as vessels
designed for Great Lakes service, certain weather restrictions pertain
to the routes in order to ensure the safety of the tow. It is up to the
tow master to review the weather forecast and interpret it against the
particular weather restrictions for the route.
    In reviewing marine weather forecast services for the routes, the
National Weather Service (NWS) Nearshore Marine Forecasts for Lake
Michigan were identified as providing localized forecasts for the
specific waters covered by the exemption routes. The Nearshore forecast
waters are a 5-mile wide corridor along the Lake shoreline. This
corridor is further divided into coastwise zones: There are five zones
between Milwaukee and Calumet, two zones between Calumet and Burns
Harbor, and seven zones beyond Burns Harbor to Muskegon. The Nearshore
forecast takes into account wind direction and speed for these zones,
and the resulting wave conditions expected over the forecast period.
    In addition to geographic coverage, the general ``Small Craft
Advisory'' (SCA) threshold conditions for the Great Lakes are sustained
winds or gusts between 22 and 33 knots inclusive, and/or seas or waves
greater than 4 feet. Small Craft Advisories may also be issued when
lake ice exists that could be hazardous to small boats.
    Although river barges are not customary small craft, the SCA
threshold conditions align closely with the weather limits for the
routes that have been in effect with the interim regulations. While the
SCA wind range is higher than the interim regulation's wind limits, the
compensating factor is that the effects of the winds are analyzed for
wave conditions in the Nearshore zones, as opposed to an open Lake
forecast. We believe that this will lead to more-accurate wave
forecasts within the Nearshore waters actually transited by the tows.
    In this regard, we believe that the use of the SCA is also a
reasonable clarification of the ``fair weather conditions'' for the
Burns Harbor route, since the zone forecast similarly considers the
effect of wind direction on wave heights along that route.
    For these reasons, the final rule substituted SCA conditions as the
limiting weather criteria for all routes because they align closely
with the interim weather limitations, and offer the benefit of
simplifying and clarifying the weather restrictions without adversely
affecting any operations. Since publishing the final rule, however, the
Coast Guard has received several comments from operators contending
that the use of SCA criteria would reduce the number of operational
days on the Burns Harbor route. Therefore, in order to provide
operators with an opportunity to comment specifically on that issue,
the Coast Guard is delaying the implementation of the SCA weather
criteria and reopening the comment period. Meanwhile, the weather
limitations that are in the present regulations, as summarized in
original Table 45.171, will remain in effect during the delay period.
All other revisions in the final rule enter into force on December 20,
2010.

Request for Public Comment

    The Coast Guard is soliciting public comment on the weather
limitations for these routes. Comments are particularly requested in
regard to the following issues:
     Suitability of the Nearshore SCA for the limiting weather
conditions.
     Alternative limiting conditions if SCA conditions are
considered excessive or otherwise inappropriate.
    We are also interested in comments regarding operator practices and
interpretation of the ``fair weather'' requirement for the Burns Harbor
route found in the interim regulations.
    This notice is issued under authority of 5 U.S.C. 553.

    Dated: December 13, 2010.
J.G. Lantz,
Director of Commercial Regulations and Standards.
[FR Doc. 2010-31699 Filed 12-16-10; 8:45 am]
BILLING CODE 9110-04-P


Episode 6000 Data 10.00 1.00 0.10 0.01 Organics, Method 1625: T= 1000Organics, 1000 BETA NAPHTHYLAMINE, NG/ ULBETA UL 0.05 0.50 5.00 50.00 1.000 0.100 0.010 0.001 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 BIS( 2 CHLOROETHYL) ETHER, NG/ ULBIS( UL 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 1625: T= 1000Organics, 1000 BUTYL BENZYL PHTHALATE, NG/ ULBUTYL UL 0.01 0.10 1.00 10.00 100.00 1.000 0.100 0.010 0.001 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 DI N BUTYL PHTHALATE, NG/ ULDI UL 5.000 Organics, Method 1625: T= 1000Organics, 1000 BIPHENYL, NG/ ULBIPHENYL, UL 1.000 0.500 1.000 0.500 0.100 0.050 0.100 0.050 0.010 0.005 0.010 0.005 0.001 Page 28 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Log 10 of Observed Standard Deviation Organics, Method 1625: T= 1000Organics, 1000 BIS( 2 CHLOROETHOXY) METHANE, NG/ ULBIS( UL 0.01 0.10 1.00 10.00 100.00 0.05 0.50 5.00 50.00 10.00 Organics, Method 1625: T= 1000Organics, 1000 BIS( 2 CHLOROISOPROPYL) ETHER, NG/ ULBIS( UL1.000 5.00 0.500 1.00 0.100 0.50 0.050 0.10 0.05 0.010 0.005 Organics, Method 1625: T= 1000Organics, 1000 BIS( 2 ETHYLHEXYL) PHTHALATE, NG/ ULBIS( UL 0.1 0.5 5.0 50.0 0.01 0.10 1.00 10.00 100.00 5.000 1.000 1.000 Organics, Method 1625: T= 1000Organics, 1000 CARBAZOLE, NG/ ULCARBAZOLE, UL 0.500 0.500 0.100 0.100 0.050 0.050 0.010 0.010 0.0050.005 0.001 0.001 0.05 0.50 5.00 50.00 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 CHRYSENE, NG/ ULCHRYSENE, UL 5.000 Organics, Method 1625: T= 1000Organics, 1000 DI N OCTYL PHTHALATE, NG/ ULDI UL 10.00 1.000 1.00 0.500 0.100 0.10 0.050 0.01 0.010 0.005 Organics, Method 1625: T= 1000Organics, 1000 DI N PROPYLNITROSAMINE, NG/ ULDI UL 0.05 0.50 5.00 50.00 0.01 0.10 1.00 10.00 100.00 Mon Mar 18 16: 30: 06 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data Organics, Method 1625: T= 1000Organics, 1000 DIBENZO( A, H) ANTHRACENE, NG/ ULDIBENZO( UL 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 DIETHYL PHTHALATE, NG/ ULDIETHYL UL 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 DIPHENYLAMINE, NG/ ULDIPHENYLAMINE, UL 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 HEXACHLOROBENZENE, NG/ ULHEXACHLOROBENZENE, UL 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 DIBENZOFURAN, NG/ ULDIBENZOFURAN, UL 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 DIMETHYL PHTHALATE, NG/ ULDIMETHYL UL 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 FLUORANTHENE, NG/ ULFLUORANTHENE, UL 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 HEXACHLOROBUTADIENE, NG/ ULHEXACHLOROBUTADIENE, UL 0.05 0.50 5.00 50.00 Page 29 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 1625: T= 1000Organics, 1000 DIBENZOTHIOPHENE, NG/ ULDIBENZOTHIOPHENE, UL 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 DIPHENYL ETHER, NG/ ULDIPHENYL UL 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 FLUORENE, NG/ ULFLUORENE, UL 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 HEXACHLOROCYCLOPENTADIENE, NG/ ULHEXACHLOROCYCLOPENTADIENE, UL 0.05 0.50 5.00 50.00 1.000 0.500 0.100 0.050 0.010 0.005 0.05 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.05 10.00 1.00 0.10 0.01 0.01 5.000 1.000 0.500 0.100 0.050 0.010 0.005 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.05 1.000 0.500 0.100 0.050 0.010 0.005 0.05 1.000 0.500 0.100 0.050 0.010 0.005 0.05 1.000 0.500 0.100 0.050 0.010 0.005 1.000 0.100 0.010 0.001 0.05 1.000 0.500 0.100 0.050 0.010 0.005 0.05 10.000 1.000 0.100 0.010 0.001 0.05 10.00 5.00 1.00 0.50 0.10 0.05 0.01 Log 10 of Observed Standard Deviation Mon Mar 18 16: 30: 20 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 1.000 1.00 0.50 0.10 0.05 Organics, Method 1625: T= 1000Organics, 1000 HEXACHLOROETHANE, NG/ ULHEXACHLOROETHANE, UL 0.01 0.10 1.00 10.00 100.00 10.00 1.00 0.10 0.01 Organics, Method 1625: T= 1000Organics, 1000 N DECANE, NG/ ULN UL 0.05 0.50 5.00 50.00 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 N EICOSANE, NG/ ULN UL 10.00 1.00 0.10 0.01 Organics, Method 1625: T= 1000Organics, 1000 N NITROSODIMETHYLAMINE, NG/ ULN UL 0.05 0.50 5.00 50.00 10.00 1.00 0.10 0.01 0.05 10.00 1.00 0.10 0.01 0.01 10.00 1.00 0.10 0.01 0.01 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.500 0.100 0.050 0.010 0.005 Page 30 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Organics, Method 1625: T= 1000Organics, 1000 ISOPHORONE, NG/ ULISOPHORONE, UL 0.50 5.00 50.00 0.05 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 N DOCOSANE, NG/ ULN UL 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 N DODECANE, NG/ ULN UL Organics, Method 1625: T= 1000Organics, 1000 N HEXACOSANE, NG/ ULN UL 5.000 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 1625: T= 1000Organics, 1000 N HEXADECANE, NG/ ULN UL 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 N NITROSODIPHENYLAMINE, NG/ ULN UL 10.00 1.00 0.10 0.01 Organics, Method 1625: T= 1000Organics, 1000 N OCTACOSANE, NG/ ULN UL 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 INDENO( 1,2,3 CD) PYRENE, NG/ ULINDENO( UL Log 10 of Observed Standard Deviation Mon Mar 18 16: 30: 35 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data 10.00 1.00 0.10 0.01 Organics, Method 1625: T= 1000Organics, 1000 N OCTADECANE, NG/ ULN UL 0.01 0.10 1.00 10.00 100.00 1.000 0.100 0.010 0.001 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 N TRIACONTANE, NG/ ULN UL 5.000 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 1625: T= 1000Organics, 1000 P CYMENE, NG/ ULP UL 0.05 0.50 5.00 50.00 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.05 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 PHENOL, NG/ ULPHENOL, UL 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.01 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.01 1.00 0.50 0.10 0.05 0.01 0.05 1.000 0.500 0.100 0.050 0.010 0.005 5.000 1.000 0.500 0.100 0.050 0.010 0.005 0.001 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 Page 31 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

Log 10 of Observed Standard Deviation Organics, Method 1625: T= 1000Organics, 1000 N TETRADECANE, NG/ ULN UL Organics, Method 1625: T= 1000Organics, 1000 NAPHTHALENE, NG/ ULNAPHTHALENE, UL 1.000 0.500 0.100 0.050 0.010 0.005 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 NITROBENZENE, NG/ ULNITROBENZENE, UL Organics, Method 1625: T= 1000Organics, 1000 PENTACHLOROPHENOL, NG/ ULPENTACHLOROPHENOL, UL 1.000 0.500 0.100 0.050 0.010 0.005 Organics, Method 1625: T= 1000Organics, 1000 PHENANTHRENE, NG/ ULPHENANTHRENE, UL 0.50 5.00 50.00 0.05 0.50 5.00 50.00 Organics, Method 1625: T= 1000Organics, 1000 PHENOL, 2 METHYL 4,6 DINITRO, NG/ ULPHENOL, UL 1.000 0.100 0.010 0.001 Organics, Method 1625: T= 1000Organics, 1000 PYRENE, NG/ ULPYRENE, UL 0.05 0.50 5.00 50.00 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 N TETRACOSANE, NG/ ULN UL Mon Mar 18 16: 30: 49 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s Episode 6000 Data Page 32 of 32Standard Deviations vs Spike Concentrations ( Log 10 Scale)

1.000 0.100 0.010 0.001 0.01 0.10 1.00 10.00 100.00 Organics, Method 1625: T= 1000Organics, 1000 STYRENE, NG/ ULSTYRENE, UL Log 10 of Observed Standard Deviation Mon Mar 18 16: 31: 04 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd1. s 0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0 Lab: 8Lab: 8 ALUMINUM, UG/ LALUMINUM, L 100 50 20 30 40 50 Lab: 7Lab: 7 ALUMINUM, UG/ LALUMINUM, L 60 60 1.0 10.0 100.0 0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0 70 Lab: 6Lab: 6 ALUMINUM, UG/ LALUMINUM, L 0.1 Lab: 5Lab: 5 ALUMINUM, UG/ LALUMINUM, L Lab: 4Lab: 4 ALUMINUM, UG/ LALUMINUM, L 20 30 20 1.0 10.0 100.0 0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0 300 Lab: 3Lab: 3 ALUMINUM, UG/ LALUMINUM, L 0.1 9 10 50 8 60 Lab: 2Lab: 2 ALUMINUM, UG/ LALUMINUM, L 9 10 70 20 90 80 Lab: 1Lab: 1 ALUMINUM, UG/ LALUMINUM, L 100 ( Matrix A, Method EPA 200.7 ICP/ AES)

Standard Deviations vs Spike Concentrations ( Log 10 Scale) Page 1 of 13AAMA Metals Data APPENDIX B  4  2 Log

10 of Observed Standard Deviation Lab: 9Lab: 9 ALUMINUM, UG/ LALUMINUM, L Log 10 of Spike Concentration Log 10 of Spike Concentration Lab: 9Lab: 9 ARSENIC, UG/

LARSENIC, L Wed Mar 20 13: 32: 49 2002 0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0 20 1 20 30 5 10 Lab: 8Lab: 8 ARSENIC, UG/

LARSENIC, L 30 Lab: 7Lab: 7 ARSENIC, UG/

LARSENIC, L 1.0 10.0 100.0 0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0 40 Lab: 6Lab: 6 ARSENIC, UG/

LARSENIC, L 0.1 7 1 20 8 Lab: 5Lab: 5 ARSENIC, UG/

LARSENIC, L 9 Lab: 4Lab: 4 ARSENIC, UG/

LARSENIC, L 10 5 30 40 1.0 10.0 100.0 0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0 50 Lab: 3Lab: 3 ARSENIC, UG/

LARSENIC, L 0.1 73 30 8 4 9 Lab: 1Lab: 1 ARSENIC, UG/

LARSENIC, L 40 10 5 6 50 Lab: 2Lab: 2 ARSENIC, UG/

LARSENIC, L 7 70 8 60 9 ( Matrix A, Method EPA 200.7 ICP/ AES)

Standard Deviations vs Spike Concentrations ( Log 10 Scale)

AAMA Metals Data Page 2 of 13Log

10 of Observed Standard Deviation c:/ pw/ ostmdl/ req005/ r005sd1. s Log

10 of Observed Standard DeviationAAMA Metals Data Page 3 of 13 Standard Deviations vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES)

6 4.0 3.0 Lab: 1Lab: 1 CADMIUM, UG/ LCADMIUM, L 5 1.0 2.0 4 Lab: 2Lab: 2 CADMIUM, UG/ LCADMIUM, L 0.5 3 1.0 0.9 0.8 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 Lab: 3Lab: 3 CADMIUM, UG/ LCADMIUM, L Lab: 5Lab: 5 CADMIUM, UG/ LCADMIUM, L 5.0 10 1.0 9 8 1.07 Lab: 4Lab: 4 CADMIUM, UG/ LCADMIUM, L 0.5 6 0.5 5 Lab: 6Lab: 6 CADMIUM, UG/ LCADMIUM, L 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 5.0 Lab: 8Lab: 8 CADMIUM, UG/ LCADMIUM, L 5.0 3.0 Lab: 7Lab: 7 CADMIUM, UG/ LCADMIUM, L 4.0 3.0 2.0 2.0 1.0 Lab: 9Lab: 9 CADMIUM, UG/ LCADMIUM, L 1.0 1.0 0.9 0.9 0.8 0.5 0.8 0.7 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 Wed Mar 20 13: 32: 51 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd1. s Log 10 of Spike Concentration 2 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 Wed Mar 20 13: 32: 53 2002 3 3 Lab: 8Lab: 8 CHROMIUM, UG/

LCHROMIUM, L 4 Lab: 7Lab: 7 CHROMIUM, UG/

LCHROMIUM, L 3 5 4 4 6 5 7 6 5 8 7 6 9 8 7 10 9 8 10 Lab: 9Lab: 9 CHROMIUM, UG/

LCHROMIUM, L9 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 10 Lab: 6Lab: 6 CHROMIUM, UG/

LCHROMIUM, L 0.1 1 5 Lab: 4Lab: 4 CHROMIUM, UG/

LCHROMIUM, L 1 6 7 9 2 8 10 3 Lab: 5Lab: 5 CHROMIUM, UG/

LCHROMIUM, L 4 5 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 5 Lab: 3Lab: 3 CHROMIUM, UG/

LCHROMIUM, L 0.1 6 Lab: 2Lab: 2 CHROMIUM, UG/

LCHROMIUM, L 0.5 1.0 7 5 8 Lab: 1Lab: 1 CHROMIUM, UG/

LCHROMIUM, L 10 5.0 9 ( Matrix A, Method EPA 200.7 ICP/ AES)

Standard Deviations vs Spike Concentrations ( Log 10 Scale)

AAMA Metals Data Page 4 of 13Log

10 of Observed Standard Deviation c:/ pw/ ostmdl/ req005/ r005sd1. s Log 10 of Spike Concentration 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 Wed Mar 20 13: 32: 55 2002 Lab: 9Lab: 9 COPPER, UG/

LCOPPER, L 0.1 5 3 10 4 5 5 6 7 8 Lab: 8Lab: 8 COPPER, UG/

LCOPPER, L 50 Lab: 7Lab: 7 COPPER, UG/

LCOPPER, L 10 9 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 10 Lab: 6Lab: 6 COPPER, UG/

LCOPPER, L 0.1 0.9 Lab: 4Lab: 4 COPPER, UG/

LCOPPER, L 1.0 40 2.0 2 3 3.0 5 4 4.0 6 Lab: 5Lab: 5 COPPER, UG/

LCOPPER, L 5.0 7 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 8 Lab: 3Lab: 3 COPPER, UG/

LCOPPER, L 0.1 Lab: 2Lab: 2 COPPER, UG/

LCOPPER, L 0.5 1 1.0 2 3 Lab: 1Lab: 1 COPPER, UG/

LCOPPER, L 5 4 10 6 5 7 ( Matrix A, Method EPA 200.7 ICP/ AES)

Standard Deviations vs Spike Concentrations ( Log 10 Scale)

AAMA Metals Data Page 5 of 13Log

10 of Observed Standard Deviation c:/ pw/ ostmdl/ req005/ r005sd1. s Log 10 of Spike Concentration Lab: 9Lab: 9 LEAD, UG/ LLEAD, L Wed Mar 20 13: 32: 57 2002 Lab: 8Lab: 8 LEAD, UG/ LLEAD, L 10 0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0 8 9 10 5 20 10 Lab: 7Lab: 7 LEAD, UG/ LLEAD, L 20 1.0 10.0 100.0 0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0 Lab: 6Lab: 6 LEAD, UG/ LLEAD, L 0.1 Lab: 5Lab: 5 LEAD, UG/ LLEAD, L 6 Lab: 4Lab: 4 LEAD, UG/ LLEAD, L 0.5 20 7 9 1.0 8 10 30 20 5.0 1.0 10.0 100.0 0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0 10.0 Lab: 3Lab: 3 LEAD, UG/ LLEAD, L 0.1 10 6 7 50 10 9 8 Lab: 2Lab: 2 LEAD, UG/ LLEAD, L 5 100 Lab: 1Lab: 1 LEAD, UG/ LLEAD, L 10 20 ( Matrix A, Method EPA 200.7 ICP/ AES)

Standard Deviations vs Spike Concentrations ( Log 10 Scale)

AAMA Metals Data Page 6 of 13Log

10 of Observed Standard Deviation c:/ pw/ ostmdl/ req005/ r005sd1. s Log 10 of Spike Concentration Wed Mar 20 13: 32: 59 2002 Lab: 9Lab: 9 MANGANESE, UG/

LMANGANESE, L Log

10 of Observed Standard Deviation 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 0.7 0.8 0.9 Lab: 8Lab: 8 MANGANESE, UG/

LMANGANESE, L 2 1.0 3 0.5 1.0 5 4 Lab: 7Lab: 7 MANGANESE, UG/

LMANGANESE, L 2.0 Lab: 6Lab: 6 MANGANESE, UG/

LMANGANESE, L 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 0.9 5 1.0 10 0.5 50 1.0 2.0 3.0 Lab: 5Lab: 5 MANGANESE, UG/

LMANGANESE, L 4.0 Lab: 4Lab: 4 MANGANESE, UG/

LMANGANESE, L 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 100 0.1 6 0.9 1.0 Lab: 3Lab: 3 MANGANESE, UG/

LMANGANESE, L 0.5 Lab: 2Lab: 2 MANGANESE, UG/

LMANGANESE, L Lab: 1Lab: 1 MANGANESE, UG/

LMANGANESE, L 1.0 ( Matrix A, Method EPA 200.7 ICP/ AES)

Standard Deviations vs Spike Concentrations ( Log 10 Scale)

AAMA Metals Data Page 7 of 13 c:/ pw/ ostmdl/ req005/ r005sd1. s Log 10 of Spike Concentration Lab: 9Lab: 9 MERCURY, UG/

LMERCURY, L Wed Mar 20 13: 33: 01 2002 0.001 0.005 0.050 0.500 0.001 0.005 0.050 0.500 0.001 0.005 0.050 0.500 0.04 0.07 0.05 0.06 0.05 0.05 0.08 Lab: 7Lab: 7 MERCURY, UG/

LMERCURY, L 0.10 0.09 0.10 Lab: 8Lab: 8 MERCURY, UG/

LMERCURY, L 0.10 0.005 0.050 0.500 0.001 0.005 0.050 0.500 0.001 0.005 0.050 0.500 0.20 Lab: 6Lab: 6 MERCURY, UG/

LMERCURY, L 0.001 0.5 0.06 0.09 0.08 0.07 0.10 Lab: 5Lab: 5 MERCURY, UG/

LMERCURY, L 1.0 0.20 0.05 Lab: 4Lab: 4 MERCURY, UG/

LMERCURY, L 0.10 0.005 0.050 0.500 0.001 0.005 0.050 0.500 0.001 0.005 0.050 0.500 0.30 Lab: 3Lab: 3 MERCURY, UG/

LMERCURY, L 0.001 0.04 0.05 0.05 0.05 0.10 Lab: 2Lab: 2 MERCURY, UG/

LMERCURY, L 0.10 0.06 0.07 Lab: 1Lab: 1 MERCURY, UG/

LMERCURY, L 0.08 0.50 0.09 ( Matrix A, Method EPA 200.7 ICP/ AES)

Standard Deviations vs Spike Concentrations ( Log 10 Scale)

AAMA Metals Data Page 8 of 13Log

10 of Observed Standard Deviation c:/ pw/ ostmdl/ req005/ r005sd1. s Log 10 of Spike Concentration 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 Wed Mar 20 13: 33: 03 2002 Lab: 9Lab: 9 MOLYBDENUM, UG/

LMOLYBDENUM, L 0.1 0.6 4 0.7 0.8 0.9 5 1.0 6 7 8 Lab: 8Lab: 8 MOLYBDENUM, UG/

LMOLYBDENUM, L 9 2.0 10 3.0 Lab: 6Lab: 6 MOLYBDENUM, UG/

LMOLYBDENUM, L 4.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.5 1.0 5 Lab: 5Lab: 5 MOLYBDENUM, UG/

LMOLYBDENUM, L 10 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 5.0 Lab: 3Lab: 3 MOLYBDENUM, UG/

LMOLYBDENUM, L 0.1 0.5 Lab: 2Lab: 2 MOLYBDENUM, UG/

LMOLYBDENUM, L 1.0 20 5.0 0.5 1.0 5.0 50.0 10.0 Lab: 7Lab: 7 MOLYBDENUM, UG/

LMOLYBDENUM, L 0.1 6 7 9 8 Lab: 4Lab: 4 MOLYBDENUM, UG/

LMOLYBDENUM, L 10 0.1 0.5 1.0 5.0 50.0 7 9 8 0.5 1.0 5.0 50.0 10 0.1 3 4 Lab: 1Lab: 1 MOLYBDENUM, UG/

LMOLYBDENUM, L 5 Log

10 of Observed Standard Deviation ( Matrix A, Method EPA 200.7 ICP/ AES)

Standard Deviations vs Spike Concentrations ( Log 10 Scale)

AAMA Metals Data Page 9 of 13 c:/ pw/ ostmdl/ req005/ r005sd1. s Log

10 of Observed Standard DeviationAAMA Metals Data Page 10 of 13 Standard Deviations vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES) 4.0 4 3.0 50 3 Lab: 1Lab: 1 NICKEL, UG/ LNICKEL, L Lab: 2Lab: 2 NICKEL, UG/ LNICKEL, L 2.0 1.02 0.9 0.8 10 0.7 0.6 Lab: 3Lab: 3 NICKEL, UG/ LNICKEL, L 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 Lab: 4Lab: 4 NICKEL, UG/ LNICKEL, L 5 30 Lab: 5Lab: 5 NICKEL, UG/ LNICKEL, L 100 50 20 Lab: 6Lab: 6 NICKEL, UG/ LNICKEL, L 1 10 5 10 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 10 5 10 9 4 Lab: 7Lab: 7 NICKEL, UG/ LNICKEL, L 5 Lab: 8Lab: 8 NICKEL, UG/ LNICKEL, L 8 7 6 35 4 1 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 Lab: 9Lab: 9 NICKEL, UG/ LNICKEL, L Wed Mar 20 13: 33: 05 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd1. s Log 10 of Spike Concentration 1.0 10.0 100.0 1000.0 0.1 1.0 10.0 100.0 1000.0 0.1 1.0 10.0 100.0 1000.0 Wed Mar 20 13: 33: 07 2002 0.1 30 20 40 5 50 30 60 10 70 Lab: 9Lab: 9 SELENIUM, UG/ LSELENIUM, L 40 50 80 90 Lab: 8Lab: 8 SELENIUM, UG/ LSELENIUM, L 100 Lab: 7Lab: 7 SELENIUM, UG/ LSELENIUM, L 1.0 10.0 100.0 1000.0 0.1 1.0 10.0 100.0 1000.0 0.1 1.0 10.0 100.0 1000.0 60 Lab: 6Lab: 6 SELENIUM, UG/ LSELENIUM, L 0.1 10 5 50 5 40 50 Lab: 5Lab: 5 SELENIUM, UG/ LSELENIUM, L 100 Lab: 4Lab: 4 SELENIUM, UG/ LSELENIUM, L 10 60 Lab: 3Lab: 3 SELENIUM, UG/ LSELENIUM, L 70 0.1 1.0 10.0 100.0 1000.0 0.1 1.0 10.0 100.0 1000.0 0.1 1.0 10.0 100.0 1000.0 7 Lab: 2Lab: 2 SELENIUM, UG/ LSELENIUM, L 5 Lab: 1Lab: 1 SELENIUM, UG/ LSELENIUM, L 8 9 50 10 100 10 20 30 40 ( Matrix A, Method EPA 200.7 ICP/ AES)

Standard Deviations vs Spike Concentrations ( Log 10 Scale)

AAMA Metals Data Page 11 of 13Log

10 of Observed Standard Deviation c:/ pw/ ostmdl/ req005/ r005sd1. s Log 10 of Spike Concentration 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 Wed Mar 20 13: 33: 09 2002 Lab: 9Lab: 9 SILVER, UG/

LSILVER, L 0.1 0.5 3 0.5 1.0 1.0 4 Lab: 8Lab: 8 SILVER, UG/

LSILVER, L 5.0 Lab: 7Lab: 7 SILVER, UG/

LSILVER, L Lab: 6Lab: 6 SILVER, UG/

LSILVER, L 5 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 40 5 Lab: 5Lab: 5 SILVER, UG/

LSILVER, L 10 0.5 1.0 Lab: 4Lab: 4SILVER, UG/

LSILVER, L 50 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 0.1 0.5 1.0 5.0 10.0 50.0 Lab: 3Lab: 3 SILVER, UG/

LSILVER, L 0.1 0.5 1 0.9 0.6 1.0 0.7 0.9 0.8 1.0 5 Lab: 2Lab: 2 SILVER, UG/

LSILVER, L 2.0 Lab: 1Lab: 1 SILVER, UG/

LSILVER, L 10 2.0 ( Matrix A, Method EPA 200.7 ICP/ AES)

Standard Deviations vs Spike Concentrations ( Log 10 Scale)

AAMA Metals Data Page 12 of 13Log

10 of Observed Standard Deviation c:/ pw/ ostmdl/ req005/ r005sd1. s Log 10 of Spike Concentration Lab: 9Lab: 9 ZINC, UG/ LZINC, L Wed Mar 20 13: 33: 11 2002 6 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 10 7 8 Lab: 7Lab: 7 ZINC, UG/ LZINC, L 5 9 10 Lab: 8Lab: 8 ZINC, UG/ LZINC, L 50 10 Lab: 6Lab: 6 ZINC, UG/ LZINC, L 100 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 1 Lab: 4Lab: 4 ZINC, UG/ LZINC, L 1 7 8 9 10 2 3 20 30 5 4 40 Lab: 5Lab: 5 ZINC, UG/ LZINC, L 5 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 0.1 0.5 1.0 5.0 50.0 10 Lab: 3Lab: 3 ZINC, UG/ LZINC, L 0.1 2 2 3 3 44 50 Lab: 2Lab: 2 ZINC, UG/ LZINC, L 5 Lab: 1Lab: 1 ZINC, UG/ LZINC, L 5 ( Matrix A, Method EPA 200.7 ICP/ AES)

Standard Deviations vs Spike Concentrations ( Log 10 Scale)

AAMA Metals Data Page 13 of 13Log

10 of Observed Standard Deviation c:/ pw/ ostmdl/ req005/ r005sd1. s Episode 6000 Data APPENDIX B  5  1 Page 1 of 32Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

Relative Standard Deviation 20 15 10 5 0 0.5 1.0 1.5 2.0 Classicals, Method 130.2Classicals, 130.2 HARDNESS, MG/ LHARDNESS, L 20 15 10 5 Classicals, Method 350.3Classicals, 350.3 AMMONIA AS NITROGEN, MG/ LAMMONIA L  3.0  2.5  2.0  1.5  1.0  0.5 0.0 50 40 30 20 10 0 01234 Metals, Method ICP/ MSMetals, MS Cd 111, pptCd ppt 600 500 400 300 200 100 0 01234 Metals, Method ICP/ MSMetals, MS Pb 206, pptPb ppt 50 40 30 20 10 0  0.5 0.0 0.5 1.0 1.5 2.0 Classicals, Method 160.2Classicals, 160.2 TOTAL SUSPENDED SOLIDS, MG/ LTOTAL L 80 60 40 20 0  2.0  1.5  1.0  0.5 0.0 Classicals, Method 365.2Classicals, 365.2 TOTAL PHOSPHORUS, MG/ LTOTAL L 140 120 100 80 60 40 20 0 01234 ( o) Metals, Method ICP/ MSMetals, MS Cu 63, pptCu ppt open circle: postitive of negative RSD value 100 80 60 40 20 0 01234 ( o) Metals, Method ICP/ MSMetals, MS Pb 207, pptPb ppt open circle: postitive of negative RSD value 50 40 30 20 10 0  0.5 0.0 0.5 1.0 1.5 ( o) ( o) ( o) Classicals, Method 1677Classicals, 1677 WAD CYANIDE, UG/ LWAD L open circle: postitive of negative RSD value 80 60 40 20 0 01234 Metals, Method ICP/ MSMetals, MS Ag 107, pptAg ppt 150 100 50 0 01234 ( o) Metals, Method ICP/ MSMetals, MS Ni 60, pptNi ppt open circle: postitive of negative RSD value 8000 6000 4000 2000 0 01234 ( o) Metals, Method ICP/ MSMetals, MS Pb 208, pptPb ppt open circle: postitive of negative RSD value Log 10 of Spike Concentration Episode 6000 Data Page 2 of 32 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

80 60 40 20 0 150 100 50 0 80 60 40 20 0 60 40 20 0 Metals, Method: ICP/ MSMetals, MS Sb 123, UG/ LSb L ( o) Metals, Method: ICP/ MSMetals, MS Se 82, UG/ LSe L open circle: positive of negative RSD value 6000 4000 2000 0 01234 01234 15000 10000 5000 0 0 1 2 3 4  1.5  1.0  0.5 0.0 0.5 1.0 ( o) ( o)( o) ( o)( o)( o)( o) ( o) Metals, Method: 1620Metals, 1620 CADMIUM, UG/ LCADMIUM, L open circle: positive of negative RSD value 140 120 100 80 60 40 20 0  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 ( o) ( o)( o) ( o) ( o)( o) ( o) Metals, Method: 1620Metals, 1620 MOLYBDENUM, UG/ LMOLYBDENUM, L open circle: positive of negative RSD value 3000 2000 1000 0  1.0  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 ( o) Metals, Method: 1620Metals, 1620 ARSENIC, UG/ LARSENIC, L open circle: positive of negative RSD value Metals, Method: ICP/ MSMetals, MS Zn 66, UG/ LZn L Metals, Method: 1620Metals, 1620 LEAD, UG/ LLEAD, L Metals, Method: 1620Metals, 1620 ANTIMONY, UG/ LANTIMONY, L 150 100 50 0 01234 Metals, Method: ICP/ MSMetals, MS Tl 205, UG/ LTl L 120 100 80 60 40 20 0  1.0  0.5 0.0 0.5 1.0 1.5 2.0 Metals, Method: 1620Metals, 1620 CHROMIUM, UG/ LCHROMIUM, L 5000 4000 3000 2000 1000 0  0.5 0.0 0.5 1.0 1.5 2.0 2.5 ( o)( o)( o) ( o) ( o) Metals, Method: 1620Metals, 1620 TIN, UG/ LTIN, L open circle: positive of negative RSD value 150 100 50 0 0.0 0.5 1.0 1.5 2.0 ( o) Metals, Method: 1620Metals, 1620 SELENIUM, UG/ LSELENIUM, L open circle: positive of negative RSD value Relative Standard Deviation Tue May 7 16: 43: 23 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd3. s Episode 6000 Data Page 3 of 32 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

500 Metals, Method: 1620Metals, 1620 THALLIUM, UG/ LTHALLIUM, L 2000 400 1500 300 1000 200 500 100 00 ( o) ( o) ( o)

( o) ( o)

( o) ( o) Metals, Method: 1620Metals, 1620 ALUMINUM, UG/ LALUMINUM, L open circle: positive of negative RSD value  1.0  0.5 0.0 0.5 1.0 1.5 2.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 800 600 400 200 0  1.0  0.5 0.0 0.5 1.0 1.5 ( o)( o) ( o) Metals, Method: 1620Metals, 1620 BARIUM, UG/ LBARIUM, L open circle: positive of negative RSD value 150 100 50 0 0.5 1.0 1.5 2.0 2.5 3.0 Metals, Method: 1620Metals, 1620 CALCIUM, UG/ LCALCIUM, L 500 400 300 200 100 0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 Metals, Method: 1620Metals, 1620 IRON, UG/ LIRON, L 80 60 40 20 0 0.5 1.0 1.5 2.0 2.5 3.0 Metals, Method: 1620Metals, 1620 NICKEL, UG/ LNICKEL, L Relative Standard Deviation 4000 3000 2000 1000 0  1.0  0.5 0.0 0.5 1.0 1.5 ( o)( o)( o) ( o) Metals, Method: 1620Metals, 1620 BERYLLIUM, UG/ LBERYLLIUM, L open circle: positive of negative RSD value 400 300 200 100 0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 Metals, Method: 1620Metals, 1620 COBALT, UG/ LCOBALT, L 100 80 60 40 20 0 1.0 1.5 2.0 2.5 3.0 3.5 Metals, Method: 1620Metals, 1620 MAGNESIUM, UG/ LMAGNESIUM, L 80 60 40 20 0 0.5 1.0 1.5 2.0 2.5 3.0 ( o) ( o)

( o) ( o)

( o) ( o) ( o) ( o)

( o) Metals, Method: 1620Metals, 1620 BORON, UG/ LBORON, L open circle: positive of negative RSD value 200 150 100 50 0  0.5 0.0 0.5 1.0 1.5 2.0 2.5 ( o)

( o) ( o) ( o) Metals, Method: 1620Metals, 1620 COPPER, UG/ LCOPPER, L open circle: positive of negative RSD value 120 100 80 60 40 20 0  1.0  0.5 0.0 0.5 1.0 1.5 2.0 Metals, Method: 1620Metals, 1620 MANGANESE, UG/ LMANGANESE, L Tue May 7 16: 43: 37 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd3. s  3 2 1 0 0 100 200 300 400 ( o) ( o) ( o) ( o)

( o) ( o) ( o) Metals, Method: 200.8Metals, 200.8 ARSENIC, UG/ LARSENIC, L open circle: positive of negative RSD value 500  101 2 0 100 200 ( o) Metals, Method: 1620Metals, 1620 ZINC, UG/ LZINC, L open circle: positive of negative RSD value 300 0  0.5 0.0 0.5 1.0 1.5 2.0 2.5 100 200 300 400 500 Metals, Method: 1620Metals, 1620 TITANIUM, UG/ LTITANIUM, L 600  0.5 0.0 0.5 1.0 1.5 2.0 2.5 0 20 40 60 80 100 Metals, Method: 200.8Metals, 200.8 BERYLLIUM, UG/ LBERYLLIUM, L 120 0  2 101  2  1 0 10 0 20 20 60 30 40 80 40 100 50 Metals, Method: 200.8Metals, 200.8 BARIUM, UG/ LBARIUM, L 60 Metals, Method: 200.8Metals, 200.8 ANTIMONY, UG/ LANTIMONY, L 1 2 3  2 101 0 Metals, Method: 200.8Metals, 200.8 ALUMINUM, UG/ LALUMINUM, L 0 20 0 40 50 60 100 150 80 Metals, Method: 1620Metals, 1620 YTTRIUM, UG/ LYTTRIUM, L 200 0.5 1.0 1.5 2.0 2.5  1.0  0.5 0.0 0.5 1.0 1.5 2.0 0.0 0 100 20 0 40 ( o) ( o) Metals, Method: 1620Metals, 1620 VANADIUM, UG/ LVANADIUM, L open circle: positive of negative RSD value 60 80 200 300 400 100 ( o) ( o) ( o) Metals, Method: 1620Metals, 1620 SODIUM, UG/ LSODIUM, L open circle: positive of negative RSD value 120 0 0.0 0.5 1.0 1.5 2.0 2.5 1.0 1.5 2.0 2.5 3.0 3.5 0 2000 2000 6000 4000 4000 8000 ( o) ( o) Metals, Method: 1620Metals, 1620 SILVER, UG/ LSILVER, L open circle: positive of negative RSD value 10000 6000 12000 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

140 Episode 6000 Data Page 4 of 32 ( o) ( o) ( o)

( o) ( o)( o)( o) ( o) Metals, Method: 200.8Metals, 200.8 CADMIUM, UG/ LCADMIUM, L open circle: positive of negative RSD value Relative Standard Deviation Tue May 7 16: 43: 51 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd3. s ( o) ( o)( o)( o)( o) ( o)

 3  2  1 0 0 20 40 60 80 Metals, Method: 200.8Metals, 200.8 COBALT, UG/ LCOBALT, L open circle: positive of negative RSD value  2  1 0 1 0 50 100 150 Metals, Method: 200.8Metals, 200.8 COPPER, UG/ LCOPPER, L  3  2  1 0 0 20 40 60 80 Metals, Method: 200.8Metals, 200.8 MANGANESE, UG/ LMANGANESE, L  2  1 0 1 0 10 20 30 40 50 Metals, Method: 200.8Metals, 200.8 MERCURY, UG/ LMERCURY, L  2  1 0 1 0 50 100 150 Metals, Method: 200.8Metals, 200.8 NICKEL, UG/ LNICKEL, L ( o) ( o)

( o)( o)( o) ( o)

 1 0 1 2 0 200 400 600 800 Metals, Method: 200.8Metals, 200.8 SELENIUM, UG/ LSELENIUM, L open circle: positive of negative RSD value ( o) ( o) ( o)

 4  3  2  1 0 20 40 60 Metals, Method: 200.8Metals, 200.8 THALLIUM, UG/ LTHALLIUM, L open circle: positive of negative RSD value  3  2  1 0 0 5 10 15 20 Metals, Method: 200.8Metals, 200.8 THORIUM, UG/ LTHORIUM, L 20 30  2 1 0 40 ( o) ( o) Metals, Method: 200.8Metals, 200.8 SILVER, UG/ LSILVER, L open circle: positive of negative RSD value  3 10 20 30 40 ( o) ( o)( o) ( o)

( o) Metals, Method: 200.8Metals, 200.8 MOLYBDENUM, UG/ LMOLYBDENUM, L open circle: positive of negative RSD value 50  3 2 1 0 0 50 100 Metals, Method: 200.8Metals, 200.8 LEAD, UG/ LLEAD, L 150  10 1 0 20 40 60 80 100 120  2 10 1 140 0 Metals, Method: 200.8Metals, 200.8 CHROMIUM, UG/ LCHROMIUM, L 10 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale) Episode 6000 Data Page 5 of 32 Relative Standard Deviation Tue May 7 16: 44: 05 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd3. s ( o) ( o) ( o)

 4  3  2  1 0 10 20 30 40 Metals, Method: 200.8Metals, 200.8 URANIUM, UG/ LURANIUM, L open circle: positive of negative RSD value ( o) ( o)( o)( o)( o) ( o) ( o)

 1 0 1 2 0 500 1000 1500 2000 Metals, Method: 200.8Metals, 200.8 VANADIUM, UG/ LVANADIUM, L open circle: positive of negative RSD value  1 0 1 2 0 20 40 60 80 100 120 140 Metals, Method: 200.8Metals, 200.8 ZINC, UG/ LZINC, L  1.0  0.5 0.0 0.5 1.0 0 20 40 60 80 100 Organics, Method: 502.2 ELCDOrganics, ELCD 1,1,1,2 TETRACHLOROETHANE, UG/ L1,1,1,2 L  1.0  0.5 0.0 0.5 1.0 10 20 30 40 Organics, Method: 502.2 ELCDOrganics, ELCD 1,1,1 TRICHLOROETHANE, UG/ L1,1,1 L  0.2 0.0 0.2 0.4 0.6 0.8 1.0 1.2 2 4 6 8 10 Organics, Method: 502.2 ELCDOrganics, ELCD 1,1,2,2 TCE+ 1,2,3 TCP, UG/ L1,1,2,2 L  1.0  0.5 0.0 0.5 1.0 0 10 20 30 40 50 Organics, Method: 502.2 ELCDOrganics, ELCD 1,1,2 TRICHLOROETHANE, UG/ L1,1,2 L  1.0  0.5 0.0 0.5 1.0 4 6 8 10 Organics, Method: 502.2 ELCDOrganics, ELCD 1,1 DICHLOROETHANE, UG/ L1,1 L  1.0  0.5 0.0 0.5 1.0 2 4 6 8 10 12 14 16 Organics, Method: 502.2 ELCDOrganics, ELCD 1,1 DICHLOROETHENE, UG/ L1,1 L  2  1 0 1 10 20 30 40 50 60 70 Organics, Method: 502.2 ELCDOrganics, ELCD 1,2,3 TRICHLOROBENZENE, UG/ L1,2,3 L  3  2  1 0 1 10 20 30 40 Organics, Method: 502.2 ELCDOrganics, ELCD 1,2,4 TRICHLOROBENZENE, UG/ L1,2,4 L  0.5 0.0 0.5 1.0 2 4 6 8 10 12 14 Organics, Method: 502.2 ELCDOrganics, ELCD 1,2 DIBROMOETHANE, UG/ L1,2 L Relative Standard Deviation Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale) Episode 6000 Data Page 6 of 32 Tue May 7 16: 44: 20 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd3. s 0  1.0  0.5 0.0 0.5 1.0  0.5 0.0 0.5 1.0 2 1 1 2 3 4 Organics, Method: 502.2 ELCDOrganics, ELCD BROMODICHLOROMETHANE, UG/ LBROMODICHLOROMETHANE, L 3 6 5 4  0.5 0.0 0.5 1.0  0.5 0.0 0.5 1.0 7 Organics, Method: 502.2 ELCDOrganics, ELCD BROMOBENZENE, UG/ LBROMOBENZENE, L  1.0 2 10 Organics, Method: 502.2 ELCDOrganics, ELCD 4 CHLOROTOLUENE, UG/ L4 L 4 6 20 8 30  0.5 0.0 0.5 1.0  1.5  1.0  0.5 0.0 0.5 1.0 40 Organics, Method: 502.2 ELCDOrganics, ELCD 1,4 DICHLOROBENZENE, UG/ L1,4 L  1.0 10 20 5 30 10 15 20 40 Organics, Method: 502.2 ELCDOrganics, ELCD 1,3 DICHLOROPROPANE, UG/ L1,3 L 50  0.5 0.0 0.5 1.0  1.5  1.0  0.5 0.0 0.5 1.0 25 Organics, Method: 502.2 ELCDOrganics, ELCD 1,2 DICHLOROPROPANE, UG/ L1,2 L  1.0 10 20 10 30 20 40 30 Organics, Method: 502.2 ELCDOrganics, ELCD 1,2 DICHLOROETHANE, UG/ L1,2 L 40 Organics, Method: 502.2 ELCDOrganics, ELCD BROMOCHLOROMETHANE, UG/ LBROMOCHLOROMETHANE, L 50 0  1.0  0.5 0.0 0.5 1.0 1 2 3 4 5  0.5 0.0 0.5 1.0 6 Organics, Method: 502.2 ELCDOrganics, ELCD 2 CHLOROTOLUENE, UG/ L2 L  1.0 5 10 15 Organics, Method: 502.2 ELCDOrganics, ELCD 1,3 DICHLOROBENZENE, UG/ L1,3 L 20 0  2.0  1.5  1.0  0.5 0.0 0.5 1.0 2 4 Organics, Method: 502.2 ELCDOrganics, ELCD 1,2 DICHLOROBENZENE, UG/ L1,2 L 6 0  1.5  1.0  0.5 0.0 0.5 1.0 20 40 60 80 100 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

Relative Standard Deviation 120 Episode 6000 Data Page 7 of 32 Organics, Method: 502.2 ELCDOrganics, ELCD BROMOFORM, UG/ LBROMOFORM, L Tue May 7 16: 44: 33 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd3. s Episode 6000 Data Page 8 of 32 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

Relative Standard Deviation 5 4 3 2 1 0.0 0.2 0.4 0.6 0.8 1.0 Organics, Method: 502.2 ELCDOrganics, ELCD BROMOMETHANE, UG/ LBROMOMETHANE, L 6 4 2 0  0.5 0.0 0.5 1.0 Organics, Method: 502.2 ELCDOrganics, ELCD CHLOROETHANE, UG/ LCHLOROETHANE, L 60 50 40 30 20 10 Organics, Method: 502.2 ELCDOrganics, ELCD CIS 1,2 DCE+ 2,2 DCP, UG/ LCIS L  1.0  0.5 0.0 0.5 1.0 6 5 4 3 2 1 0  1.0  0.5 0.0 0.5 1.0 Organics, Method: 502.2 ELCDOrganics, ELCD DIBROMOMETHANE, UG/ LDIBROMOMETHANE, L 20 15 10 5  1.0  0.5 0.0 0.5 1.0 Organics, Method: 502.2 ELCDOrganics, ELCD CARBONTET+ 1,1 DCP, UG/ LCARBONTET+ L 25 20 15 10 5  1.0  0.5 0.0 0.5 1.0 Organics, Method: 502.2 ELCDOrganics, ELCD CHLOROFORM, UG/ LCHLOROFORM, L 7 6 5 4 3 2 1  1.0  0.5 0.0 0.5 1.0 Organics, Method: 502.2 ELCDOrganics, ELCD CIS 1,3 DICHLOROPROPENE, UG/ LCIS L 30 25 20 15 10 5 0  1.0  0.5 0.0 0.5 1.0 Organics, Method: 502.2 ELCDOrganics, ELCD DICHLORODIFLUOROMETHANE, UG/ LDICHLORODIFLUOROMETHANE, L 8 6 4 2 0  1.0  0.5 0.0 0.5 1.0 Organics, Method: 502.2 ELCDOrganics, ELCD CHLOROBENZENE, UG/ LCHLOROBENZENE, L 6 5 4 3 2 1 0  2.0  1.5  1.0  0.5 0.0 0.5 1.0 Organics, Method: 502.2 ELCDOrganics, ELCD CHLOROMETHANE, UG/ LCHLOROMETHANE, L 5 4 3 2 1 0  1.0  0.5 0.0 0.5 1.0 Organics, Method: 502.2 ELCDOrganics, ELCD DIBROMOCHLOROMETHANE, UG/ LDIBROMOCHLOROMETHANE, L 100 80 60 40 20 0  3 2 10 1 Organics, Method: 502.2 ELCDOrganics, ELCD HEXACHLOROBUTADIENE, UG/ LHEXACHLOROBUTADIENE, L Tue May 7 16: 44: 47 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd3. s Organics, Method: 502.2 PIDOrganics, PID 1,3,5 TMB+ 4 CHLOROTOLUENE, UG/ L1,3,5 L  1.5 10 20 30 40 50  1.0  0.5 0.0 0.5 1.0 60 Organics, Method: 502.2 PIDOrganics, PID 1,2,4 TRICHLOROBENZENE, UG/ L1,2,4 L  1.5 10 20 30 0.0 0.5 1.0 40 Organics, Method: 502.2 ELCDOrganics, ELCD TRICHLOROFLUOROMETHANE, UG/ LTRICHLOROFLUOROMETHANE, L  0.5 5 10 Organics, Method: 502.2 ELCDOrganics, ELCD TRANS 1,2 DICHLOROETHENE, UG/ LTRANS L 15  1.0  0.5 0.0 0.5 1.0 4 6 8 10 12  0.5 0.0 0.5 1.0 14 Organics, Method: 502.2 PIDOrganics, PID 1,2 DICHLOROBENZENE, UG/ L1,2 L  1.0 6 16 14 12 10 8 Organics, Method: 502.2 PIDOrganics, PID 1,2,3 TRICHLOROBENZENE, UG/ L1,2,3 L 18  2 10 1 0 20 40 60 80  0.5 0.0 0.5 1.0 100 Organics, Method: 502.2 ELCDOrganics, ELCD TRICHLOROETHENE, UG/ LTRICHLOROETHENE, L  1.0 5 10  1.0  0.5 0.0 0.5 1.0 15 Organics, Method: 502.2 ELCDOrganics, ELCD TETRACHLOROETHENE, UG/ LTETRACHLOROETHENE, L  1.5 20 40  1.0  0.5 0.0 0.5 1.0 60 Organics, Method: 502.2 PIDOrganics, PID 1,2,4 TRIMETHYLBENZENE, UG/ L1,2,4 L  1.5 5 10 Organics, Method: 502.2 ELCDOrganics, ELCD VINYL CHLORIDE, UG/ LVINYL L 15  0.5 0.0 0.5 1.0 1 2 3 4 5 Organics, Method: 502.2 ELCDOrganics, ELCD TRANS 1,3 DICHLOROPROPENE, UG/ LTRANS L 6 0  1.0  0.5 0.0 0.5 1.0 1 2 3 4 5  0.5 0.0 0.5 1.0 6 Organics, Method: 502.2 ELCDOrganics, ELCD METHYLENE CHLORIDE, UG/ LMETHYLENE L  1.0 10 20 30 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

Relative Standard Deviation 40 Episode 6000 Data Page 9 of 32  1.0  0.5 0.0 0.5 1.0 Tue May 7 16: 45: 00 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd3. s Organics, Method: 502.2 PIDOrganics, PID N PROPYLBENZENE, UG/ LN L  1.5 10 2 Organics, Method: 502.2 PIDOrganics, PID N BUTYLBENZENE, UG/ LN L 20 30 4 40 6 50 8 Organics, Method: 502.2 PIDOrganics, PID ISOPROPYLBENZENE, UG/ LISOPROPYLBENZENE, L 10  2  1 0 1  1.0  0.5 0.0 0.5 1.0 5 0 20 10 10 15 30 40 Organics, Method: 502.2 PIDOrganics, PID HEXCHLOBUTADIENE+ NAPHTHALENE, UG/ LHEXCHLOBUTADIENE+ L 20 Organics, Method: 502.2 PIDOrganics, PID CIS 1,3 DICHLOROPROPENE, UG/ LCIS L 50  1.5  1.0  0.5 0.0 0.5 1.0  1.0  0.5 0.0 0.5 1.0 10 0 20 20 40 40 30 60 50 Organics, Method: 502.2 PIDOrganics, PID CHLOROBENZENE, UG/ LCHLOROBENZENE, L 80  1.0  0.5 0.0 0.5 1.0  1.0  0.5 0.0 0.5 1.0 60 Organics, Method: 502.2 PIDOrganics, PID BENZENE, UG/ LBENZENE, L  1.5 20 10 20 Organics, Method: 502.2 PIDOrganics, PID 2 CHLOROTOLUENE, UG/ L2 L 30 40 60 40  1.0  0.5 0.0 0.5 1.0 50 Organics, Method: 502.2 PIDOrganics, PID M+ P XYLENE, UG/ LM+ L  1.5 5 10 15 20  1.0  0.5 0.0 0.5 1.0 25 Organics, Method: 502.2 PIDOrganics, PID ETHYLBENZENE, UG/ LETHYLBENZENE, L  1.5 5 10 15 20 25  1.0  0.5 0.0 0.5 1.0 30 Organics, Method: 502.2 PIDOrganics, PID BROMOBENZENE, UG/ LBROMOBENZENE, L  1.5 5 10  1.0  0.5 0.0 0.5 1.0 15 Organics, Method: 502.2 PIDOrganics, PID 1,3 DICHLOROBENZENE, UG/ L1,3 L  1.5 20 40 60 80 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

Relative Standard Deviation 100 Episode 6000 Data Page 10 of 32  1.0  0.5 0.0 0.5 1.0  1.5  1.0  0.5 0.0 0.5 1.0 Tue May 7 16: 45: 14 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req004/ r004sd3. s